ENTBD 17m o/s with two new products in a 15bil under represented market about to make a huge move...radar if looking for a mid term hold...sister company on verge for FDA clinical trial approval (sept/Oct) will have impact. Recent R/S caused a share recount, last two weeks trading shows a massive short squeeze taking place
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.